Comments
Glenmark Pharmaceuticals has received final approval from the US health regulator for Tacrolimus ointment used for treating atopic dermatitis (eczema).
Glenmark Pharmaceuticals Inc USA has been granted final approval by the United States Food and Drug Administration (USFDA) for Tacrolimus ointment USP, 0.1 per cent, the company said in a BSE filing today.
The product is a generic version of Protopic ointment of Leo Pharma AS in the same strength. According to IQVIA sales data for the 12-month period ended February 2018, Protopic ointment 0.1 per cent achieved annual sales of around $109 million, Glenmark Pharmaceuticals said.
The company’s current portfolio consists of 132 products authorised for distribution in the US market and 61 Abbreviated New Drug Applications (ANDAs) pending approval with the USFDA, it added.
Shares of Glenmark Pharmaceuticals were trading up by 0.38 per cent at Rs 576 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.